Furthermore, the main chemokines in this pathway, namely CXCL12 and CXCL13, were significantly downregulated in IBD patients who responded to anti-TNF agents and were upregulated in nonresponders. The gene discussed is CXCL13; the disease is inflammatory bowel disease.